Lets be honest, whilst the revenue growth rates impressive are...

Lets be honest, whilst the revenue growth rates impressive are off too low a base to address its cash burn enough for many investors (not me personally) and it is why the stock trades where it does. The share price needs OSX to pluck some cash from one its existing A*star or SingHealth partnerships or its alluded to negotations with Innoventure or (less likely) CellHeal in the short-term to address mkts (i.e. investors) concerns over its bank balance. Investors get overly nervous about non-positive cash flow stocks in the present high cost of capital environment.

For me the improvement in gross profits is impressive enough to slow the cash burn significantly in the next quarters, if, (IF) the change in revenues and expenses continues (Admin and other general expenses still too high for all their bleating on costs savings):



A simple extrapolation of revenues and cost of sales (gross profits +95%) for the next year at the same growth rates would see it, with non-cost of sales expenses held the same, would see it report a lowly -$195K operating loss next year. Ergo, it wouldn't need another raise - naturally the fear of many investors in the stock right now. Some cash from a partnership clearly is going to address those fears far more effectively than even simple basic financial analysis.